The DOI matches its Crossref record.
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
Abstract
A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) regimen. The patients received an allogeneic marrow (n = 3) or peripheral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1 Ag-mismatched related (n = 1), donors. RIC regimens included fludarabine/total body irradiation 200 cGy (n = 5) or 450 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1). At the time of transplantation, all of the patients were at intermediate (n = 13) or high (n = 8) risk, according to the Dupriez classification. Of the patients, 19 had grade III or IV marrow fibrosis. All of the patients achieved full engraftment but one. Posttransplantation chimerism analysis showed more than 95% donor cells in 18 patients, while 2 patients achieved complete donor chimerism after donor leukocyte infusion (DLI). Acute graft-versus-host disease (GVHD) grades II to IV was observed in 7 patients, grades III to IV in 2, and extensive chronic GVHD in 8 of 18 evaluable patients. There were 3 patients who died from acute GVHD, infection, and relapse. There are 18 patients alive 12 to 122 months (median, 31 months) after transplantation, and 17 are in remission (1 after a second transplantation). The use of RIC regimens in allogeneic stem cell transplantation results in prolonged survival in intermediate/high-risk MMM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationRole of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., et al. (2009) · Blood · doi:10.1182/blood-2009-07-234880 · Cited by 396
Schneider, R. K., Mullally, A., Dugourd, A., Peisker, F., Hoogenboezem, R., Van Strien, P. M. H., Bindels, E. M., Heckl, D., Büsche, G., Fleck, D., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.03.008 · Cited by 272
Metadata
- Authors
- Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J. T., Popat, U., Alessandrino, E. P., Spivak, J. L., Smith, B. D., Klingemann, H. G., Fruchtman, S., & Hoffman, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-05-15
- Volume
- 105
- Issue
- 10
- Pages
- 4115-4119
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2129219546
- Cited by
- 199
- References
- 0
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. https://app.cochat.ai/papers/10.1182/blood-2004-11-4299
- The paper
- Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J. T., Popat, U., Alessandrino, E. P., Spivak, J. L., Smith, B. D., Klingemann, H. G., Fruchtman, S., & Hoffman, R. (2005). Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. https://doi.org/10.1182/blood-2004-11-4299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.